Strata Skin Sciences

What Strata Skin Sciences does

Strata Skin Sciences is a Horsham, Pennsylvania-based medical technology company that develops, places, and supports dermatologic treatment devices in dermatology practices, hospitals, and academic medical centers. Its core portfolio is built around 308-nm excimer laser and lamp platforms — the XTRAC excimer laser and VTRAC excimer lamp for psoriasis, vitiligo, leukoderma, and atopic dermatitis — plus the TheraClearX photopneumatic system for mild-to-moderate acne and the Pharos excimer laser acquired from Ra Medical Systems. XTRAC treatments are covered by most major insurers and Medicare and are supported by a direct-to-patient Patient Advocate Team that handles coverage and reimbursement inquiries.

The company generates revenue primarily through device placement combined with recurring procedure-based utilization on the installed base, and operates a B2B enterprise field sales motion targeting mid-market dermatology practices as well as named academic medical centers including Johns Hopkins, NYU, Cleveland Clinic, Cornell, and UC. The 2021 acquisition of Ra Medical's U.S. dermatology business added approximately 430 practice accounts and materially expanded the recurring-revenue footprint. International expansion is being pursued via distributor partnerships, exemplified by the MINO Labs arrangement in Mexico following COFEPRIS clearance of TheraClearX in October 2025.

Financially, Strata is a small, cash-constrained, loss-making public company that voluntarily delisted from Nasdaq in February 2026 (Form 25 filed; trading suspended February 19, 2026), with cumulative net losses each year across the disclosed 2021-2025 period and revenue pressure in 2025 attributed to international softness. Capital structure consists of a $12 million MidCap Financial refinancing (July 2023, maturing June 2028), a $2.42 million registered direct offering in September 2025, and a 2024 financing round, alongside approximately $8 million in cash at fiscal year-end 2025 per company commentary. Key strategic pillars going forward are the AMA CPT reimbursement expansion for XTRAC effective January 1, 2027, the Mexico rollout of TheraClearX, and ongoing academic partnership-driven clinical evidence generation.

Name

Strata Skin Sciences

Legal name

STRATA Skin Sciences, Inc.

Website

https://strataskinsciences.com

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Strata Skin Sciences is a Pennsylvania-based medical technology company that places 308-nm excimer laser and lamp devices (XTRAC, VTRAC, Pharos) and the TheraClearX acne system in dermatology practices and academic medical centers, generating recurring procedure-based revenue across roughly 430 practice accounts.

Ownership category

akta.pro rank

Product category

Dermatology Medical Devices

NAICS

Irradiation Apparatus Manufacturing (334517), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Laser & Energy-Based Dermatology (HLAKACAF)

akta.pro secondary industries

Psoriasis & Eczema Specialty Care (HLAKACAL), Professional Skincare & Facial Treatments (CRABALAF), Dermatology Specialty Pharmaceuticals (HLAIACAL)

Keywords

• Dermatology medical devices
• Excimer laser systems
• UVB phototherapy
• Acne treatment systems
• Dermatologic light therapy

Headquarters

HQ city

Horsham

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. XTRAC/VTRAC Device Placement and Recurring Revenue: STRATA places its excimer laser and lamp systems in dermatology practices and hospitals. Revenue is generated through device placements and recurring revenue from consumable/procedural usage, with recurring revenue stream from treatment procedures performed on installed systems. The acquisition of Ra Medical's dermatology business (including approximately 430 dermatology practices) expanded the recurring revenue customer base significantly.
2. Pharos Excimer Laser System: The Pharos excimer laser system acquired from Ra Medical Systems is used for treating chronic skin diseases and contributes to expanded market share and recurring revenue stream through existing dermatology practice accounts.
3. TheraClearX Acne Treatment System: The TheraClearX system is commercialized through placements in dermatology and aesthetic practices, with revenue generated from device placement and associated treatments. Expanded internationally via COFEPRIS clearance in Mexico with first commercial placements in Mexico City.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

STRATA Skin Sciences develops, manufactures, and places proprietary dermatologic treatment devices into clinical practices and academic medical centers. Its flagship XTRAC 308-nm excimer laser and VTRAC excimer lamp deliver targeted UVB phototherapy for psoriasis, vitiligo, atopic dermatitis, and leukoderma, while the TheraClearX system uses photopneumatic technology to treat mild-to-moderate acne. The company also commercializes the Pharos excimer laser acquired from Ra Medical Systems, and generates recurring revenue from treatment procedures performed on installed devices.

Product overview

STRATA Skin Sciences develops and markets dermatologic treatment products centered around excimer laser and light therapy technologies. The core product portfolio includes the XTRAC excimer laser (308nm UVB for psoriasis and vitiligo), the TheraClearX acne treatment system (photopneumatic technology), and the VTRAC excimer lamp system. The company also acquired the Pharos excimer laser system through its acquisition of Ra Medical Systems' U.S. dermatology business. Products are primarily sold to dermatologists, plastic surgeons, and aesthetic professionals, with treatments covered by major insurance and Medicare.

Differentiator

Problem solved

Functional benefit

Brands

• XTRAC: 308 nm excimer laser system for treatment of psoriasis and vitiligo using targeted UVB phototherapy.
• VTRAC
• TheraClearX

Products and services

• XTRAC Excimer Laser The XTRAC is a 308-nm excimer laser system that delivers a highly targeted therapeutic beam of UVB light to treat psoriasis and vitiligo without damaging surrounding healthy skin. It achieves 95% clearance of psoriasis lesions in 10-12 treatments, is quick and virtually painless, and is covered by most major insurance companies and Medicare. It is sold or placed into dermatology practices and academic medical centers for use by board-certified dermatologists.
• TheraClearX Acne Treatment System TheraClearX is a non-invasive, in-office acne treatment system designed for mild-to-moderate acne. It uses photopneumatic technology that combines vacuum with broadband light delivered through a liquid-cooled hand-held delivery system, and is commercialized through placements in dermatology and aesthetic practices.
• VTRAC Excimer Lamp System The VTRAC is a 308-nm excimer lamp system with a water-cooled handpiece for maximum irradiance. As a light source rather than a laser, it offers targeted therapeutic efficacy with the simplicity and reliability of a lamp system for treating psoriasis, vitiligo, leukoderma, and atopic dermatitis.
• Pharos Excimer Laser System The Pharos is an excimer laser system used for treating chronic skin diseases. Acquired from Ra Medical Systems as part of the U.S. dermatology business acquisition, it contributes to expanded recurring revenue from existing dermatology practice accounts.

Quantifiable outcome

• 95% clearance of psoriasis lesions in 10-12 treatments
• +3 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• MINO LabscoreChannel Partner/ Reseller/ Distributor · 28 October 2025STRATA partnered with MINO Labs for the distribution of TheraClearX in Mexico following COFEPRIS regulatory approval. MINO Labs is facilitating the commercial rollout of the TheraClearX acne treatment system in Mexico, with first placement in Mexico City and plans to expand to other major cities and develop clinical data and broader indications.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Sciton: Sciton manufactures laser and light platforms for dermatologists and plastic surgeons, including BBL and fractional devices used in chronic skin condition and aesthetic treatments. It targets the same dermatology practice channel as Strata with overlapping use cases.
• Cynosure: Cynosure is a global developer of light-based aesthetic and dermatology treatment systems. It serves overlapping customer segments (dermatologists, plastic surgeons, med-spas) with a broader portfolio of laser/IPL platforms that compete with Strata's XTRAC and TheraClearX.
• Alma Lasers: Alma Lasers is a global provider of energy-based aesthetic and medical devices used in dermatology, plastic surgery, and medical spa settings. It competes with Strata in dermatology treatment systems but operates across a much broader indication and modality portfolio.
• Candela Medical: Candela (formed from the Syneron-Candela combination) is a global aesthetic and medical device company with laser, IPL, and energy-based systems for skin and dermatology indications. It is a broad incumbent whose product portfolio directly competes with Strata's excimer and photopneumatic platforms.
• Lumenis: Lumenis is a long-established developer of medical laser and energy-based devices for dermatology, aesthetics, and surgical applications. It competes broadly with Strata in laser-based dermatologic treatment and represents a much larger incumbent in the same energy-device category.
• Solta Medical: Solta Medical (a Bausch Health franchise) makes energy-based devices such as Fraxel, Clear+Brilliant, and Thermage used in dermatology and aesthetics. It serves the same dermatologist and plastic surgeon customers with broader skin treatment offerings.

Direct peers

• Cutera: Cutera manufactures laser and energy-based aesthetic and dermatology systems sold to practices and med-spas, with a similar placement-plus-recurring-revenue model. It competes directly with Strata for dermatology practice capital equipment budgets.
• Aerolase: Aerolase develops portable 650-microsecond aesthetic and medical laser systems for dermatology indications including acne, psoriasis, and pigmentation. It is a direct competitor in dermatology lasers with overlapping indications treated by TheraClearX.
• Venus Concept: Venus Concept sells energy-based aesthetic and dermatologic treatment systems via a placement/subscription business model to practices and med-spas. Its capital-light, recurring-revenue approach closely mirrors Strata's XTRAC placement model.

Others

• PhotoMedex (now part of RTI Surgical / RA Medical legacy): PhotoMedex was historically a direct competitor in excimer laser dermatology devices (XTRAC's predecessor technology era). It remains thematically relevant as a comparable dermatology excimer/UVB therapy device peer whose assets and IP overlap with the broader market Strata competes in.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/10618870

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strata Skin Sciences